GlassScriptPhysician profile
Radhika Chugh
NPI 1427398247
$10,927.29
in general payments reported to CMS, 2019-2025
51 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $896 · 2021: $911 · 2022: $2,064 · 2023: $2,397 · 2024: $2,109 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,713.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,319.24 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $1,241.04 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,082.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $615.31 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $598.72 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $587.23 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $547.42 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $496.45 | 2021-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $478.85 | 2019-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.44 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $369.40 | 2019-2024 | |
| Corcept Therapeutics | $255.97 | 2020-2023 | Korlym |
| Radius Health, INC. | $203.61 | 2020-2024 | Tymlos |
| Medtronic, INC. | $197.40 | 2021-2025 | Minimed 780g |
| Pfizer INC. | $167.02 | 2020-2024 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $163.48 | 2019-2021 | |
| Nevro Corp. | $162.85 | 2021-2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $157.37 | 2020-2025 | Farxiga |
| Horizon Therapeutics Plc | $147.60 | 2021-2023 | Tepezza |
| Amryt Pharma Holdings LTD | $145.63 | 2021-2022 | |
| Abbvie INC. | $144.43 | 2019-2025 | Synthroid |
| Recordati_rare_diseases_inc. | $136.74 | 2021-2025 | Isturisa, Signifor Lar |
| Merz North America, INC. | $135.67 | 2022 | |
| Neurocrine Biosciences, INC. | $126.64 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $112.17 | 2023-2025 | Baqsimi |
| Ascendis Pharma Endocrinology INC | $75.66 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $75.14 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $72.36 | 2020 | |
| Ascensia Diabetes Care US INC. | $68.61 | 2024 | |
| Medtronic Minimed, INC. | $64.89 | 2019-2020 | |
| Allergan, INC. | $59.41 | 2019 | |
| Roche Diabetes Care, INC. | $46.30 | 2021 | |
| Tandem Diabetes Care, INC. | $41.44 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $39.94 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $35.89 | 2022 | |
| Mannkind Corporation | $35.38 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $30.57 | 2025 | Tryngolza |
| Lifescan, INC. | $29.55 | 2020 | |
| Sandoz INC. | $29.37 | 2025 | Jubbonti |
| Ibsa Pharma INC. | $29.29 | 2020 | |
| Merck Sharp & Dohme LLC | $26.70 | 2022-2023 | Steglatro, Januvia |
| Averitas Pharma INC. | $24.38 | 2025 | Qutenza |
| Zealand Pharma US, INC. | $23.56 | 2021 | |
| Antares Pharma, INC. | $23.08 | 2022 | |
| Sequel Med Tech, LLC | $22.33 | 2025 | Twiist |
| Eusa Pharma (US) LLC | $21.45 | 2022 | |
| Grt US Holding, INC. | $17.91 | 2022 | |
| Tersera Therapeutics LLC | $15.04 | 2023 | Xermelo |
| Beta Bionics, INC. | $14.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $11.01 | 2022 | |
| Clarus Therapeutics INC. | $10.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radhika Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.